🇺🇸 FDA
Pipeline program

Nexviadyme 100 mg powder for concentrate for solution for infusion

GZ-2016-11512

Approved small_molecule active

Quick answer

Nexviadyme 100 mg powder for concentrate for solution for infusion for Glycogen storage disease type II or acid maltase deficiency, Pompe disease is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Glycogen storage disease type II or acid maltase deficiency, Pompe disease
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials